Annual deaths from cancer have dropped 27% in the last 25 years, according to the American Cancer Society (ACS). However, the death rates for some have barely dropped, and some forms will still kill…
Heat waves swung through Phoenix the week and pushed temperatures as high as 110 degrees Fahrenheit. In New Delhi, India, the temperature rose close to 120 but was pushed down fairly quickly by strong…
ArQule shares jumped early on Friday after the firm announced preliminary results from an early-stage study in patients with relapsed or refractory hematologic malignancies at the 2019 European Hematology Association annual meeting.
Savara shares were absolutely crushed on Thursday after the company released its late-stage results for its treatment of autoimmune pulmonary alveolar proteinosis. Unfortunately, the study did not meet its primary endpoint.
Whether you were in favor of or against the Affordable Care Act, it is likely of little surprise that the cost of health care has continued to rise. What also has risen handily is…
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The May 31 short interest data have been compared with the previous report, and short interest in most of these…
The May 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
One relatively small clinical-stage biopharmaceutical player called Global Blood Therapeutics may be about to change how sickle cell disease treatment goes.
Zynerba Pharma has just announced that the U.S. Patent and Trademark Office has issued a patent for the firm’s treatment of autism spectrum disorder with cannabidiol.
CymaBay Therapeutics shares were nearly halved early Tuesday after the company provided an update from its midstage study of seladelpar for the treatment of nonalcoholic steatohepatitis.
A monoclonal antibody called teplizumab has been shown to delay the onset of type 1 diabetes for as long as two years. About 1.25 million Americans suffer from the disease, a form of diabetes…
ReWalkshares took a step back on Monday after the firm announced that it would be pricing a registered direct offering for $5 million. This comes after the stock had a phenomenal week when the…